NCT06427668Active, not recruitingPhase 2
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302
Source: ClinicalTrials.gov · Last updated 17 Aug 2025
Brief summary (registry, in English)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 13 May 2024
- Start date
- 29 Jul 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- Spinogenix
- Diseases
- Alzheimer disease
- NCT number
- NCT06427668
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 24
- From 29 Jul 2024 to the primary completion date, Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Vaccines within 14 days
- Receipt of investigational products within 30 days
Other illness
- Any physical or psychological condition that prohibits study completion
- Known cardiac disease
- Active or history of malignancy in the past 5 years
- Serious infection that will not be resolved by first day of study intervention.
- History of clinically significant CNS event or diagnosis in the past 5 years.
- Acute illness within 30 days of Day 1
- History of suicidal behavior or suicidal ideation
- History of chronic alcohol use or substance abuse in the last 5 years
- HIV, hepatitis B and/or hepatitis C positive
Other
- Blood donation within 30 days
- Pregnant or breastfeeding
Who the study is looking for
- Age 45-85
- Diagnosis of mild to moderate AD
- Clinical laboratory values within normal range or \< 1.5 times ULN
- If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug.
- Life expectancy of \>2 years
- Able and willing to provide written informed consent
Age in the registry: 45 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Flinders Medical center Coordinator of this site? Confirm its status | Adelaide | Australia | Unknown status |
| St Vincent's Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.